Search This Blog

Tuesday, May 13, 2025

Federal Judge Says Trump's Invocation Of Alien Enemies Act Was Legal

 by Sam Dorman via The Epoch Times,

A federal judge in Pennsylvania has said that President Donald Trump validly invoked the Alien Enemies Act in March as part of an effort to deport Venezuelan gang members.

More specifically, U.S. District Judge Stephanie Haines held that the gang - Tren de Aragua (TdA) - was engaging in the type of “predatory incursion” that the Alien Enemies Act mentions.

In an opinion on May 13, Haines noted that TdA has been designated a foreign terrorist organization. 

That designation, she said, “heavily supports the conclusions ... that TdA is a cohesive group united by a common goal of causing significant disruption to the public safety of the United States.”

Haines, a Trump appointee, emphasized her “unflagging obligation is to apply the law as written.” 

“Having done its job, the Court now leaves it to the Political Branches of the government, and ultimately to the people who elect those individuals, to decide whether the laws and those executing them continue to reflect their will,” Haines wrote in her 43-page ruling.

Three other district court judges have ruled against the Trump administration, stating that Trump misapplied the law with a proclamation he issued in March. 

Each of those judges disagreed with Trump’s description of TdA as engaging in an invasion or predatory incursion.

The government can now proceed, so long as they provide 21-days’ notice to migrants in both English and Spanish.

“The Court recognizes that it may need to conduct further analysis and consider additional issues related to the specifics of notice in the future,” Haines wrote.

“However, at this preliminary stage of this case, the Court finds that the foregoing is appropriate and complies with the law.”

https://www.zerohedge.com/political/federal-judge-says-trumps-invocation-alien-enemies-act-was-legal

Capricor (CAPR) On Track for Duchenne Cardiomyopathy Therapy Approval

 Capricor Therapeutics (CAPR, Financial) is progressing significantly towards its objective of delivering the first approved treatment for Duchenne cardiomyopathy, a condition that currently lacks approved therapies. The company is actively engaging with the FDA as it evaluates their Biologics License Application (BLA), with a target action date set for August 31, 2025, under the Prescription Drug User Fee Act (PDUFA). Preparations are underway for forthcoming FDA advisory committee meetings, pre-approval inspections, and the anticipated commercial launch.

Simultaneously, Capricor's StealthX vaccine program is poised to begin Phase 1 clinical trials in the third quarter of 2025. This initiative is spearheaded by the National Institute of Allergy and Infectious Diseases (NIAID) as part of Project NextGen, pending regulatory approval from NIAID. Financially, Capricor concluded the first quarter of the year with a robust cash reserve of approximately $145 million, positioning the company well to continue its strategic initiatives as it approaches key milestones.

https://www.gurufocus.com/news/2860141/capricor-capr-on-track-for-duchenne-cardiomyopathy-therapy-approval-capr-stock-news

EPA chief Lee Zeldin to kill stop-start car feature ‘everyone hates’

 Environmental Protection Agency Administrator Lee Zeldin hinted Monday that he’s preparing to roll back one car feature that every driver “hates.”

“Start/stop technology: where your car dies at every red light so companies get a climate participation trophy,” Zeldin tweeted Monday in a post that has since racked up more than 8 million views.

“EPA approved it, and everyone hates it, so we’re fixing it.”

The feature kills internal combustion engines at red lights and has been touted by proponents for being able to conserve fuel and cut down on pollution.

Critics have questioned whether the feature can wear down the car’s battery or engine more quickly.

Environmental Protection Agency Administrator Lee Zeldin hinted Monday that he’s preparing to roll back one car feature that every driver “hates.”REUTERS
The “off-cycle CO2 reducing” tech has its origins in a federal rule proposed under former President Barack Obama in 2012 — but didn’t take effect until new fuel economy standards to reduce greenhouse gas emissions five years later.

Between 2012 and 2021, the number of vehicles produced with a stop-start feature due to the carbon credits surged from 1% to 45%.

Up to 65% of vehicles had the technology included in new models by 2023.

Up to 65% of vehicles had the technology included in new models by 2023.Lee Zeldin/X

The smart start tech can improve fuel economy by between 4% and 5%, according to past EPA estimates.

But it hasn’t shown clear reductions in emissions tests, an EPA spokesperson noted.

If finalized, automakers could no longer receive any credits to produce the stop-start tech in new models.

If finalized, automakers could no longer receive any credits to produce the stop-start tech in new models.phantom1311 – stock.adobe.com

Reps for the largest auto industry trade group, the Alliance for Automotive Innovation, did not immediately respond to a request for comment.

The move follows Zeldin targeting other tax incentives from a New York climate law and green grants from the Biden administration as part of a renewable energy push. 

Zeldin charged that New York Gov. Kathy Hochul unwisely ended “safe extraction” of natural gas, gas hookups on new building construction, and gas stoves — but sought to cut sales of gas-powered vehicles and block the new Constitution Pipeline’s construction.

In January, the EPA head revealed that he found $20 billion in taxpayer money “parked” at Citibank in Manhattan after it was authorized for an array of “far-left activist groups” following the passage of Biden’s Inflation Reduction Act.

President Trump tapped Zeldin to “unleash prosperity through deregulation” with an executive order in January that designated the EPA and other agencies to eliminate at least 10 regulations for every new one proposed.

https://nypost.com/2025/05/13/us-news/epa-chief-lee-zeldin-to-kill-car-feature-everyone-hates/

Designing safe, effective nasal vaccines

 Most vaccines—and boosters—are injected directly into muscle tissue, usually in the upper arm, to kickstart the body's immune system in the fight against disease. But for respiratory diseases like COVID-19, it can be important to have protection right where the virus enters: the respiratory tract.

In a new study, Yale researchers have found that nasal vaccine boosters can trigger strong immune defenses in the respiratory tract, even without the help of immune-boosting ingredients known as adjuvants. The findings, researchers suggest, may offer critical insights into developing safer, more effective nasal vaccines in the future.

"Our study shows how a simple viral protein antigen can boost respiratory tract immune responses against viruses," said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine (YSM) and senior author of the study. "These data imply that viral proteins in  may be used as a safe way to promote antiviral immunity at the site of viral entry."

The study was published today in the journal Nature Immunology. The first author is Dong-il Kwon, a postdoctoral fellow in Yale's Department of Immunobiology.

For the study, the researchers first injected mice with a traditional mRNA COVID-19 shot, which was injected directly into the muscle. Then, the team gave the mice a  through the nose. The team specifically wanted to evaluate the effects of vaccine boosters that don't contain special ingredients known as adjuvants. Used in some vaccines, adjuvants help stimulate a stronger, longer-lasting immune response, but they can also have adverse effects like inflammation and swelling of facial nerves.

"We call this vaccine strategy 'prime and spike,' which is where the mice were intramuscularly primed with mRNA vaccines followed by a nasal boosting with unadjuvanted spike protein," said Kwon, who is a member of Iwasaki's lab.

The Yale-developed "prime and spike" vaccine approach jump-starts immune response in the respiratory system—the first part of the body infected by COVID-19. "Prime" refers to the process of administering a traditional intramuscular vaccine shot, while "spike" refers to a follow-up vaccination delivered to the nose—usually in the form of a spray containing coronavirus-derived spike proteins.

After the first shot,  became primed in the lymph nodes of the mice. After the nasal booster, B cells from the lymph node migrated to the lungs and produced immunoglobulin A (IgA), an antibody that helps protect the nose and lungs from infection. Memory CD4+ helper T cells acted as natural adjuvants by recruiting B cells and helping them secrete IgA in the lung.

Only the nasal booster triggered this strong local immune response, the researchers found. Boosters given other ways, including intramuscular injection, didn't produce much IgA or activate immune cells in the lungs of the mice. When the researchers gave the mice a second nasal booster, their IgA levels increased even more in both the lungs and nasal passages.

"These findings help explain why nasal boosters do not require adjuvant to induce robust mucosal immunity at the respiratory mucosa and can be used to design safe and effective vaccines against respiratory virus pathogens," Kwon said.

Regular COVID-19 shots don't create much IgA in the nose and lungs. So, people can still get infected or pass it on, even if they're vaccinated. But this study shows that nasal boosters can trigger strong, long-lasting immune protection where  like COVID-19 first attack.

"Understanding how this safe and simple nasal booster promotes protective mucosal immunity will make it easier to develop this approach for human use in the near future," Iwasaki said.

Iwasaki is also a professor of dermatology and of molecular, cellular, and  in Yale's Faculty of Arts and Sciences, a professor of epidemiology (microbial diseases) at Yale School of Public Health, and an investigator at the Howard Hughes Medical Institute.

Other Yale authors include Tianyang Mao, a former graduate student who is now a postdoctoral fellow at the Broad Institute of MIT and Harvard; Benjamin Israelow, assistant professor of medicine (infectious diseases) at YSM; Keyla Santos Guedes de Sá, a postdoctoral associate; and Huiping Dong, a research assistant.

More information: Dong-il Kwon et al, Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice, Nature Immunology (2025). DOI: 10.1038/s41590-025-02156-0


https://medicalxpress.com/news/2025-05-insights-safe-effective-nasal-vaccines.html

The Deep State Goes Viral

Via The Brownstone Institute,

The following is Jeffrey Tucker’s Foreword introduction to Debbie Lerman’s new book, The Deep State Goes Viral: Pandemic Planning and the Covid Coup.

It was about a month into lockdowns, April 2020, and my phone rang with an unusual number. I picked up and the caller identified himself as Rajeev Venkayya, a name I knew from my writings on the 2005 pandemic scare. Now the head of a vaccine company, he once served as Special Assistant to the President for Biodefense, and claimed to be the inventor of pandemic planning. 

Venkayya was a primary author of “A National Strategy for Pandemic Influenza” as issued by the George W. Bush administration in 2005. 

It was the first document that mapped out a nascent version of lockdowns, designed for global deployment. 

“A flu pandemic would have global consequences,” said Bush, “so no nation can afford to ignore this threat, and every nation has responsibilities to detect and stop its spread.”

It was always a strange document because it stood in constant contradiction to public health orthodoxies dating back decades and even a century. 

With it, there were two alternative paths in place in the event of a new virus: the normal path that everyone is taught in medical school (therapeutics for the sick, caution with social disturbances, calm and reason, quarantines only in extreme cases) and a biosecurity path that invoked totalitarian measures. 

Those two paths existed side-by-side for a decade and a half before the lockdowns. 

Now I found myself speaking with the guy who claims credit for having mapped out the biosecurity approach, which contradicted all public health wisdom and experience. His plan was finally being implemented. Not too many voices dissented, partially due to fear but also due to censorship, which was already very tight. He told me to stop objecting to the lockdowns because they have everything under control. 

I asked a basic question. Let’s say we all hunker down, hide under the sofa, eschew physical meetings with family and friends, stop all gatherings of all kinds, and keep businesses and schools closed. What, I asked, happens to the virus itself? Does it jump in a hole in the ground or head to Mars for fear of another press conference by Andrew Cuomo or Anthony Fauci? 

After some fallacy-filled banter about the R-naught, I could tell he was getting exasperated with me, and finally, with some hesitation, he told me the plan. There would be a vaccine. I balked and said that no vaccine can sterilize against a fast-mutating respiratory pathogen with a zoonotic reservoir. Even if such a thing did appear, it would take 10 years of trials and testing before it was safe to release to the general population. Are we going to stay locked down for a decade?

“It will come much faster,” he said. “You watch. You will be surprised.”

Hanging up, I recall dismissing him as a crank, a has-been with nothing better to do than call up poor writers and bug them. 

I had entirely misread the meaning, simply because I was not prepared to understand the sheer depth and vastness of the operation now in play. All that was taking place struck me as obviously destructive and fundamentally flawed but rooted in a kind of intellectual error: a loss of understanding of virology basics. 

Around the same time, the New York Times posted without fanfare a new document called PanCAP-A: Pandemic Crisis Action Plan – Adapted. It was Venkayya’s plan, only intensified, as released on March 13, 2020, three days before President Trump’s press conference announcing the lockdowns. I read through it, reposted it, but had no idea what it meant. I hoped someone could come along to explain it, interpret it, and tease out its implications, all in the interest of getting to the bottom of the who, what, and why of this fundamental attack on civilization itself. 

That person did come along. She is Debbie Lerman, intrepid author of this wonderful book that so beautifully presents the best thoughts on all the questions that had eluded me. She took the document apart and discovered a fundamental truth therein. The rule-making authority for the pandemic response was not vested in public-health agencies but the National Security Council.

This was stated as plain as day in the document; I had somehow missed that. This was not public health. It was national security. The antidote under development with the label vaccine was really a military countermeasure. In other words, this was Venkayya’s plan times ten, and the idea was precisely to override all tradition and public health concerns and replace them with national security measures. 

Realizing this fundamentally changes the structure of the story of the last five years. This is not a story of a world that mysteriously forgot about natural immunity and made some intellectual error in thinking that governments could shut down economies and turn them back on again, scaring a pathogen back to where it came from. What we experienced in a very real sense was quasi-martial law, a deep-state coup not only on a national but on an international level. 

These are terrifying thoughts and hardly anyone is prepared to discuss them, which is why Lerman’s book is so crucial. In terms of public debate about what happened to us, we are barely at the beginning. There is now a willingness to admit that the lockdowns did more overall harm than good. Even the legacy media has started venturing out to grant permission for such thoughts. But the role of the pharmaceuticals in driving the policy and the role of the national-security state in backing this grand industrial project is still taboo. 

In 21st-century journalism and advocacy designed to influence the public mind, the overwhelming concern of all writers and institutions is professional survival. That means fitting into an approved ethos or paradigm regardless of the facts. This is why Lerman’s thesis is not debated; it is hardly spoken of at all in polite society. That said, my work at Brownstone Institute has put me in close contact with many thinkers in high places. This much I can say: what Lerman has written in this book is not disputed but admitted in private. 

Strange isn’t it? We saw during the Covid years how professional aspiration incentivized silence even in the face of egregious violations of human rights, including mandatory school closures that robbed children of education, followed by face-covering requirements and forced injections for the whole population. The near-silence was deafening even if anyone with a brain and a conscience knew that all of this was wrong. Not even the excuse that “We didn’t know” works anymore because we did know. 

This same dynamic of social and cultural control is fully in operation now that we are through that stage and onto another one, which is precisely why Lerman’s findings have not yet made their way to polite society, to say nothing of mainstream media. Will we get there? Maybe. This book can help; at least it is now available for everyone brave enough to confront the facts. You will find herein the most well-documented and coherent presentation of answers to the core questions (what, how, why) that all of us have been asking since this hell was first visited upon us. 

https://www.zerohedge.com/covid-19/deep-state-goes-viral

Student Loan Delinquencies Surge, Hammer Credit Scores - Southern States Hit Hardest

 The party is over for millions of Americans who paused payments on their federal student loans over the last several years through pandemic-era forbearance programs. Many had hoped for sweeping loan forgiveness under the Biden-Harris administration, But with the federal government officially resuming collections on defaulted loans this month—for the first time in over five years—borrowers now face sliding credit scores as delinquencies soar, while in April we warned the restart could drain as much as $63 billion from the economy. 

On Tuesday, the Center for Microeconomic Data at the New York Fed released its Quarterly Report on Household Debt and Credit, updated through the first quarter of 2025.

Within the report is a snapshot of consumer credit profiles, including the sharp rise in delinquent student loan debt that's now piling up.

Starting with a 10,000-foot view; in the first quarter of 2025 the aggregate U.S. delinquency rate climbed to 4.3% of outstanding debt in some stage of delinquency - up from 3.6% in the fourth quarter of 2024. Total aggregate household debt increased by $167 billion in the quarter, up .9% from 4Q24, while overall, America's consumer debt balance now stands at a whopping $18.20 trillion - an increase of more than $4 trillion since 4Q19.

Narrowing it down, while early-stage delinquency rates remained stable across most debt categories, student loans bucked the trend, posting a sharp increase as the federal government resumed credit reporting on missed payments for the first time in nearly five years.

"Transition into early delinquency held steady for nearly all debt types; the exception was for student loans, which saw a large uptick in the rate at which balances went from current to delinquent due to the resumption of reporting of delinquent student loans on credit reports after a nearly 5-year pause due to the pandemic," the quarterly report said. 

The shift comes amid the expiration of pandemic-era forbearance, exposing millions of borrowers to renewed repayment obligations

Last month, Education Secretary Linda McMahon told President Trump at a Cabinet meeting: 

"We're going to start getting it back," adding "For those people who have borrowed money and have not been paying -- that's just not to be punitive, there are many ways that they can go online to understand how they can get back into the right payment structure. Because when they're in default, they can't buy a house, they can't buy a car, their credit scores go down."

Also reported last month (full note available to premium subs), student-loan delinquencies have increased since the pandemic-era forbearance on repayment ended in September 2023. The Biden administration allowed a year for payments to fully ramp back up, which temporarily suppressed delinquency rates. Now, though, missed payments are crossing the 90-day threshold and showing up on borrowers' credit reports.

Transition rates into serious delinquency (90+ days past due) held steady for auto loans and credit cards, but rose for mortgages, HELOCs, and, notably, student loans, reflecting growing financial strain among consumers.

Bloomberg noted: 

Transitioning into serious delinquency (90-plus days late) for student loans rose to tie a 10-year-old record for those age 50 and older. Among that cohort, 11.23%, or around one in nine households, is now seriously delinquent on their student loan debt. Americans age 50 and older held $418.5 billion in student loan debt, split among 9.2 million borrowers. The ratios of serious delinquency for younger age groups was lower but still rose sharply. The average age of a delinquent borrower ticked up to 40.4.

The Fed's data shows that the credit hit is substantial for newly delinquent student loan borrowers. Among the 7.5% who had a relatively high credit score of at least 720 before the delinquency, their scores dropped by 177 points on average. Overall, the Fed found that 2.2 million borrowers saw their credit scores drop by at least 100 points.

Data from Bloomberg shows the student debt bubble stood at a record high of $1.63 trillion. 

New York Fed economists via Liberty Street Economics published a note with more color about the student loan turmoil unfolding, indicating "more than twenty million federal borrowers were not in repayment and five million federal borrowers had a zero dollar monthly payment," adding, "Among borrowers who were required to make payments, nearly one in four student loan borrowers (23.7 percent) were behind on their student loans in the first quarter of 2025." 

The economists noted that seven states have a conditional borrower delinquency rate over 30%: Mississippi (44.6%), Alabama (34.1%), West Virginia (34.0%), Kentucky (33.6%), Oklahoma (33.6%), Arkansas (33.5%), and Louisiana (31.8%). These states are located in the heartland and are primarily Trump states

The economists offered their take on the grave situation:

After a five-year hiatus, student loan delinquency has returned to the pre-pandemic "normal" with more than 10 percent of balances and roughly six million borrowers either past due or in default. The ramifications of student loan delinquency are severe.

The U.S. Department of Education, in concert with the U.S. Treasury, began collection efforts for defaulted loans in May, which includes the garnishment of wages, tax returns, and Social Security payments.

Additionally, millions of borrowers face steep declines in their credit standing which will increase borrowing costs or seriously limit their access to credit like mortgages and auto loans. It is unclear whether these penalties will spill over into payment difficulties in other credit products, but we will continue to monitor this space in the coming months.

Millennials and GenX feeling the brunt of student debt woes. 

Credit score downgrades begin... 

More:

What's critical to understand is that delinquent student loan debt continues to pile up quickly, increasingly hitting borrowers' credit reports. This growing wave of defaults could trigger a domino effect on consumer spending, potentially dragging down GDP by as much as $63 billion—a risk we warned about in our note titled The Next Economic Shock: Student Loan Default Wave = $63 Billion GDP Hit ...

.   .   .

View the full report here:

Nutex Health Q1 2025 Earnings: EPS of $2.56 Beats Estimates, Revenue Soars to $211.8 M

 

  • Revenue: $211.8 million, significantly surpassing the estimated $117.70 million, marking a 213.8% increase from Q1 2024.
  • Net Income: Achieved $14.6 million, a substantial turnaround from a net loss of $0.4 million in Q1 2024.
  • Earnings Per Share (EPS): Reported at $2.56, exceeding the estimated EPS of $2.29 and improving from $(0.08) in Q1 2024.
  • EBITDA: Reached $43.1 million, a 507.0% increase compared to $7.1 million in Q1 2024.
  • Adjusted EBITDA: Recorded at $72.8 million, a significant improvement from $(0.4) million in Q1 2024.
  • Net Cash from Operating Activities: Achieved a record high of $51.0 million, indicating strong operational cash flow.